Place of parenteral cephalosporins in the ambulatory setting: Clinical evidence

Drugs

Volumn 59, Issue SUPPL. 3, 2000, Pages 37-46

  Nathwani, Dilip ^a  

^a King's Cross Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFALEXIN; CEFAZOLIN; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; PROBENECID; SULTAMICILLIN; TEICOPLANIN; VANCOMYCIN;

ACUTE PYELONEPHRITIS; BACTERIAL INFECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH CARE COST; HUMAN; INFUSION PUMP; LENGTH OF STAY; OUTPATIENT CARE; PATIENT COMPLIANCE; PELVIC INFLAMMATORY DISEASE; PREGNANCY; REVIEW; SEPSIS; TREATMENT OUTCOME;

EID: 0033921393     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059003-00005     Document Type: Review

References (62)

1. Bamberger DM, Dahl SL. Impact of voluntary vs enforced compliance of third-generation use in a teaching hospital. Ann Intern Med 1992; 152: 554-7
2. Plumridge RJ. Cost comparison of intravenous antibiotic administration. Med J Aust 1990; 153: 516-8
3. MacGregor RR, Graziani A. Oral administration of antibiotics: a rational alternative to parenteral route. Clin Infect Dis 1997; 24: 457-67
4. Bartlett JG. Impact of new oral antibiotics on the treatment of infectious diseases. Infect Dis Clin Pract 1993; 2: 405-13
5. Halls GA. The management of infections and antibiotic therapy: a European survey. J Antimicrob Chemother 1993; 31: 985-1000
6. Tice AD. Outpatient parenteral antibiotic therapy in different countries. Int J Infect Dis 1996; 1: 102-6
7. Tice AD. Experience with a physician-directed, clinic-based program for outpatient parenteral antibiotic therapy in the USA. Eur J Clin Microbiol Infect Dis 1995; 14: 655-61
8. Balinsky W, Nesbitt S. Cost-effectiveness of outpatient antibiotics: a review of the literature. Am J Med 1989; 87: 301-5
9. Poretz DM, Wollard D, Eron LJ, et al. Outpatient use of ceftriaxone: a cost-benefit analysis. Am J Med 1984; 77 Suppl. 4C: 77-83
10. Daly PB, Evans JH, Kobayashi RH, et al. Home based immunoglobulin infusion therapy: quality of life and patient health perceptions. Ann Allergy 1991; 67: 504-10
11. Williams DN. Home intravenous antibiotic therapy (HIVAT): indications, patients, and antimicrobial agents. Int J Antimicrob Agents 1995; 5: 3-8
12. Kunkel MJ. Quality assurance. Hosp Pract 1993; 28 Suppl. I: 33-8
13. Conlon CP. Outpatient intravenous antibiotic therapy. J Antimicrob Chemother 1996; 38: 557-9
14. Nathwani D, Seaton A, Davey P. Key issues in the development of a non-inpatient intravenous (NIPIV) antibiotic therapy programme - a European perspective. Rev Med Microbiol 1997; 8 (3): 137-48
15. Vinks AATMM, Touw DJ, Heijerman HGM, et al. Pharmaco-kinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Ther Drug Monit 1994; 16 (4): 341-8
16. Tice AD, Slama TG, Berman S, et al. Managed care and the infectious diseases specialist. Clin Infect Dis 1996; 23: 341-68
17. Anonymous. Canadian Home IV Guidelines. Canadian Advisory Committee on Home IV Antibiotic Therapy. Toronto, Canada: Canadian Advisory Committee, 1994: 1-8
18. Nathwani D, Tillotson G, Davey P. Sequential antibiotic therapy - the role of quinolones. J Antimicrob Chemother 1997; 39 (4): 441-6
19. Huchon GJ, Gialdroni-Grassi G, Leophonte P, et al. Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey. Eur Resp J 1996; 9: 1590-5
20. Misan GMH, Dollman C, Shaw D, et al. Cephalosporin utilisation review and utilisation. Pharmacoeconomics 1995; 8 (2): 100-22
21. Adu AA, Armour CL. Drug Utilisation Review (DUR) of the third generation cephalosporins. Drugs 1995, 50 (3): 423-39
22. Mandell LA, Bergeron MG, Gribble MJ, et al. Sequential antibiotic therapy: effective cost management and patient care. Can J Infect Dis 1995; 6 (6): 306-15
23. Hamilton-Miller JMT. Switch therapy: the theory and practice of early change from parenteral to non-parenteral antibiotic administration. Clin Microbiol Infect Dis 1996; 2: 12-20
24. Nathwani D. Outpatient treatment with teicoplanin. Chemotherapie J 1996; 5 Suppl. 11: 35-8
25. Wilson APR, Gruneberg RN. Use of teicoplanin in community medicine. Eur J Clin Microbiol Infect Dis 1994; 13: 701-10
26. Davis R, Bryson HM. Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections. Pharmacoeconomics 1994; 6 (3): 249-69
27. Talan DA. Infectious disease issues in the emergency department. Clin Infect Dis 1996; 23: 1-14
28. Craig WA. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. Eur J Clin Microbiol Infect Dis 1995; 14: 636-42
29. Jauregui LE, Martin M, Hageage G. Clinical evaluation of ceftriaxone therapy in the out-patient setting. Insights into the Treatment of Serious Infections 1988; 2: 186-94
30. Eron LJ, Park CH, Hixon DH, et al. Ceftriaxone therapy of bone and soft tissue infections in the outpatient and hospital settings. Antimicrob Agents Chemother 1983; 23: 731-7
31. Stamboulian D, Bonvehi P, Arevalo C, et al. Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci. Rev Infect Dis 1991; 13 Suppl. 2: S160-3
32. Francioli P, Etienne J, Hoigne R, et al. Treatment of streptococcal endocarditis with a single dose of ceftriaxone sodium for 4 weeks. JAMA 1992; 267: 264-7
33. Francioli P, Ruch W, Stamboulian D and the International Infective Endocarditis Study Group. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicentre study. Clin Infect Dis 1995; 21: 1406-10
34. Karachalios GN, Georgiopoulos AN, Kanatakis S. Treatment of various infections in an outpatient practice by intramuscular ceftriaxone: home parenteral therapy. Chemotherapy 1989; 35: 389-92
35. Russo TA, Cook S, Gorbach SL. Intramuscular ceftriaxone in home parenteral therapy. Antimicrob Agents Chemother 1988; 32: 1439-40
36. Bass JW, Steele RW, Wittler RR, et al. Antimicrobial treatment of occult bacteremia: a multicenter cooperative study. Pediatr Infect Dis J 1993; 12: 466-73
37. Preis S, Jugens H, Friedland C, et al. Ceftriaxone alone or in combination with teicoplanin in the management of febrile episodes in neutropenic children and adolescents with cancer on an outpatient basis. Klin Padiatr 1993; 205: 295-9
38. Martino P, Girmenia C, Raccah R, et al. Single daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day hospital for hematologic malignancies. Oncology 1992; 49: 49-52
39. Kaplinsky C, Drucker M, Goshen J, et al. Ambulatory treatment with ceftriaxone in febrile neutropenic children. Isr J Med Sci 1994; 30: 649-51
40. Mustafa MM, Aquino VM, Pappo A, et al. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. J Pediatr 1996; 128: 847-9
41. Leibovitz E, Tabachnik E, Fliedel O, et al. Once-daily intramuscular ceftriaxone in the outpatient treatment of severe community acquired pneumonia in children. Clin Pediatr 1991; 29: 634-9
42. Bradley JS, Ching DK, Phillips SE. Outpatient therapy of serious pediatric infections with ceftriaxone. Pediatr Infect Dis J 1988; 7: 160-4
43. Dagan R, Einhorn M. A program of outpatient parenteral antibiotic therapy for serious pediatric bacterial infections. Rev Infect Dis 1991; 13 Suppl. 2: S152-5
44. McCarthy CA, Powell KR, Jaskiewicz JA, et al. Outpatient management of selected infants younger than two months of age evaluated for possible sepsis. Pediatr Infect Dis J 1990; 9: 385-9
45. Baskin MC, O'Rourke EJ, Fleisher GR. Outpatient treatment of febrile infants 28 to 89 days of age with intramuscular administration of ceftriaxone. J Pediatr 1992; 120: 22-7
46. Morales JO, Snead H. Efficacy and safety of intravenous cefotaxime for treating pneumonia in outpatients. Am J Med 1994; 97 Suppl. 2A: 28-33
47. Williams DN, Bosch D, Boots J, et al. Safety, efficacy, and cost savings in an outpatient intravenous antibiotic program. Clin Ther 1993; 15 (1): 169-79
48. Mauceri AA and the HIAT Group. Treatment of bone and joint infections utilising a third generation cephalosporin with an outpatient drug delivery device. Am J Med 1994; 97 Suppl. 2A: 14-22
49. Poretz DM and the HIAT Group. Treatment of skin and soft tissue infections utilising an outpatient parenteral drug delivery device: a multicenter trial. Am J Med 1994; 97 Suppl. 2A: 23-7
50. Williams DN. Reducing costs and hospital stay for pneumonia with home intravenous cefotaxime treatment: results with a computerised ambulatory drug delivery system. Am J Med 1994; 97 Suppl. 2A: 50-5
51. Poretz DM and the HIAT Group. Treatment of serious infections with cefotaxime utilizing an outpatient drug delivery device: global analysis of a large-scale, multicenter trial. Am J Med 1994; 97 Suppl. 2A: 34-42
52. Angel JVG and the HIAT Group. Outpatient antibiotic therapy for elderly patients. Am J Med 1994; 97 Suppl. 2A: 43-9
53. Morales JO, Behren LV. Secondary bacterial infections in the HIV-infected patients: an alternative ambulatory outpatient treatment utilising intravenous cefotaxime. Am J Med 1994; 97 Suppl. 2A: 9-13
54. Tice A. Once-daily ceftriaxone outpatient therapy in adults with infections. Chemotherapy 1991; 37 Suppl. 3: 7-10
55. Parker S, Nathwani D, O'Reilly D, et al. Evaluation of the impact of non-inpatient iv antibiotic treatment for acute infections on the hospital, primary care services and the patient. J Antimicrob Chemother 1998; 42: 373-80
56. Lieu TA, Baskin MN, Schwartz S, et al. Clinical and cost-effectiveness of outpatient strategies for the management of febrile infants. Pediatrics 1992; 89: 1135-44
57. van der Laag J, van de Weg L. Cystic fibrosis and outpatient treatment with parenteral antibiotics in children. Int J Antimicrob Agents 1995; 5: 63-6
58. Millar LK, Wing D, Paul RH, et al. Outpatient treatment of pyelonephritis in pregnancy: a randomized controlled trial. Obstet Gynecol 1995; 86 (4): 560-4
59. Koeesim M, Ronald A, Plummer FA, et al. Treatment of acute pelvic inflammatory disease in the ambulatory selling: trial of cefoxitin and doxycyline versus ampicillin-sulbactam. Antimicrob Agents Chemother 1991; 35 (8): 1651-6
60. Arredondo JL, Diaz V, Gaitan H, et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clin Infect Dis 1997; 24: 170-8
61. New PB, Swanson GF, Bulich RG, et al. Ambulatory antibiotic infusion devices: extending the spectrum of outpatient therapies. Am J Med 1991; 91: 455-61
62. Nathwani D, Conlon C. Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a Working Party. Clin Microbiol Infect Dis 1998; 4: 537-51